Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Rhea-AI Summary

Atossa Therapeutics (Nasdaq: ATOS) has appointed Michael Parks as Vice President of Investor and Public Relations. With nearly 30 years of experience in the biopharmaceutical and healthcare industries, Parks will oversee corporate communications, investor relations, and branding for the company. Atossa, a clinical-stage biopharmaceutical company, focuses on developing innovative medicines for breast cancer and other areas of unmet medical need in oncology.

Parks' extensive background includes roles at PAVmed, Lucid Diagnostics, Liquidia , and his own consulting firm, Pitch360. He also held positions at Johnson & Johnson's Centocor, Pfizer, Pharmacia, and Searle Pharmaceuticals. Dr. Steven Quay, Atossa's CEO, expressed excitement about Parks joining the team, highlighting his seasoned experience and multidisciplined approach to communications.

Positive

• Appointment of experienced communications professional to lead investor and public relations
• Potential for improved stakeholder communication and brand awareness

Negative

• None.

SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

“We are excited to welcome Michael to Atossa. Michael is a highly seasoned corporate communications professional with experience across healthcare companies of all sizes and stages of development,” said Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa. “His extensive experience and multidisciplined approach to communications will serve Atossa well in advancing the story of the immense potential of the (Z)-endoxifen platform for patients and translating this opportunity into value for investors and other stakeholders.”

Prior to joining Atossa, Mr. Parks was Vice President of Investor Relations at both PAVmed, a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors; and its publicly traded subsidiary, Lucid Diagnostics, a commercial-stage, cancer prevention medical diagnostics company. Previously, Mr. Parks led corporate communications and public affairs efforts at Liquidia Corporation after serving more than a decade as the Founder and President of Pitch360, a consulting firm which provided a full spectrum of investor relations, corporate communications and public affairs services to private and small-cap biopharmaceutical companies. Earlier in his career he served as the Vice President of Corporate Communications at Centocor, a Johnson & Johnson Company, and held roles of increasing responsibility at Pfizer, Pharmacia, and Searle Pharmaceuticals.  

“I am thrilled to join Atossa at such a pivotal time in the company’s history,” said Mr. Parks. “Atossa’s commitment to advancing innovative therapies in oncology, particularly in breast cancer, aligns perfectly with my passion for communicating impactful stories to the healthcare, investor, and patient communities. I look forward to joining this dedicated team on this journey and continue building value and awareness among Atossa’s multiple stakeholders.”

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. For more information, please visit www.atossatherapeutics.com.

Contact:

Michael Parks
VP, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com

FAQ

Who is Michael Parks and what is his new role at Atossa Therapeutics (ATOS)?

Michael Parks has been appointed as Vice President of Investor and Public Relations at Atossa Therapeutics (ATOS). He brings nearly 30 years of experience in investor relations and corporate communications within the biopharmaceutical and healthcare industries.

What are Michael Parks' responsibilities in his new role at Atossa Therapeutics (ATOS)?

In his new role at Atossa Therapeutics (ATOS), Michael Parks will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the company.

What is Atossa Therapeutics' (ATOS) primary focus in drug development?

Atossa Therapeutics (ATOS) is a clinical-stage biopharmaceutical company focused on developing innovative medicines in oncology, with a particular emphasis on breast cancer and areas of significant unmet medical need.

What is the significance of Michael Parks joining Atossa Therapeutics (ATOS)?

Michael Parks joining Atossa Therapeutics (ATOS) is significant due to his extensive experience in healthcare communications. His expertise is expected to help advance the company's story, particularly regarding the potential of the (Z)-endoxifen platform, and translate opportunities into value for investors and stakeholders.